Articles by Hans Hammers, MD, PhD
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
In part 3 of the session, the panel discusses the latest developments in treatments for papillary kidney cancer.
In the second part of the session, the panel highlights some of the most important recent developments in papillary RCC.
In part one of the session, the panelists dive into an in-depth exploration and debate on the results of SUNNIFORECAST.
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
View the live recording of the "The Uromigos' Definition of Oligometastatic" session from Uromigos Live 2024.
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
The Role of SBRT and Metastasis-Directed Therapy for RCC Treatment, Variant Histology Considerations
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.